Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group.
about
Economic considerations in the management of Alzheimer's diseaseCholinesterase inhibitors for Alzheimer's diseaseGalantamine for Alzheimer's disease and mild cognitive impairmentRosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III studyLong-term course and effectiveness of combination therapy in Alzheimer diseasePlacebo effects: clinical aspects and neurobiologyCurrent pharmacologic options for patients with Alzheimer's diseaseTo what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers?Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysisDrug Development in Alzheimer's Disease: The Contribution of PET and SPECTNatural Phytochemicals in the Treatment and Prevention of Dementia: An OverviewSystematic Review: Representativeness of Participants in RCTs of Acetylcholinesterase InhibitorsEffects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trialCloning and characterization of a norbelladine 4'-O-methyltransferase involved in the biosynthesis of the Alzheimer's drug galanthamine in Narcissus sp. aff. pseudonarcissusA novel approach to delayed-start analyses for demonstrating disease-modifying effects in Alzheimer's diseaseCognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking.Treatment guidelines for Alzheimer's disease: redefining perceptions in primary care.Galantamine facilitates acquisition of a trace-conditioned eyeblink response in healthy, young rabbits.The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial.Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials.Early Diagnosis and Treatment of Dementia Presenting as Transient Global Amnesia in a 76-Year-Old Man.Cholinesterase inhibitors: drugs looking for a disease?Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects.Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease.The Effects of an Uninterrupted Switch from Donepezil to Galantamine without Dose Titration on Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease.Care of older people: Mental health problemsDiscontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer's Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 Patients.Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer diseaseCholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.Advances in the pharmacotherapy of Alzheimer's disease.A searchable cross-platform gene expression database reveals connections between drug treatments and disease.Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer's disease: comparison of efficacy and effectiveness studies.Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease.Treatment of dementia with neurotransmission modulation.Efficacy and Tolerability of a Combination Treatment of Memantine and Donepezil for Alzheimer's Disease: A Literature Review Evidence.Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease.Galantamine: a new alzheimer drug with a past life.Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohortCurrent status and new developments with galantamine in the treatment of Alzheimer's disease.
P2860
Q22241448-9C4F5308-DDB7-44B1-8413-C96B782E0B22Q22252975-6AB85A57-CD37-428B-B0FB-DBA7DF925006Q24244773-EF1147ED-8859-4E7F-9169-BB0B5B3C7EF7Q24628969-C01220C0-1227-4658-AAA1-DFE27839D34FQ24642161-7365C086-522D-432B-9B8A-01560559BFB7Q24653735-3C608469-73F2-4F0C-ABBB-70F23B5E3A24Q24800530-E3118623-F2FF-4A5B-90F5-06162EB0F25EQ24800672-62B1C63F-EC45-4D27-85A3-EFFD4B41DC5CQ24805169-2BB61C0B-FD12-4233-ADC9-4F1BAE5D6E82Q26749755-EC7D52CA-39F0-42C3-88E2-7BE5B0D47A06Q26750581-AB3B0951-EBCE-44E3-A964-5406301E379DQ26863383-C11DA599-DE14-4D93-AAB2-4085EC9C2903Q28362149-16B0C2A5-2313-4596-BD3E-7BB84F4982C6Q28541214-3239F3FE-2CF3-4521-ADCE-ED222B4D2D34Q28544423-EF014B5F-F648-46A8-891E-D0DD25DD11CDQ30396291-679C7BCB-A3BE-42E5-B90C-75B0C3B7F0D8Q30443975-27901216-703B-4D03-B87C-AD6DBA384917Q30500431-609E999A-ACF2-4A82-9863-15D22AB19D6AQ30874688-DE27EA82-831F-4CFA-80F1-475570C3F721Q33160127-B8F133AC-B15A-4A39-9AF2-DA405B35ABE5Q33210272-56F82282-2803-4CC3-8363-EDA244B0C151Q33238993-E1FC3D76-B077-4C48-8831-F14499C777A4Q33759397-DCC76DE8-D67B-4F0E-9AB1-5FEDAF6489E5Q33790288-289830F9-A81C-42DD-BE72-5EB09750CAF1Q33795194-00F3C9F5-1BEB-4725-9A1D-B26018DD2A04Q33804768-560DBA79-AF89-42A4-9B60-4B0FB73A4134Q33858264-707F5284-7EBB-4DD3-A81A-0D506525DB80Q33867858-31A55E04-272D-46D0-AD7D-C38624401629Q33912750-7BEFFE2E-4C78-4816-88D5-564221643457Q34011160-DDD51945-5569-438D-BA0C-58844ACBDB11Q34123013-D74E2721-A02C-433B-B12F-48FF33B0E148Q34156798-EACC2008-7931-4FE2-814C-9E548106EBA5Q34233759-8F30DAA8-48B8-46E7-9B54-AA7157B3B87BQ34266258-20DAA4BC-C838-4B1C-8ED1-B13631A4BBF3Q34301111-573935FC-1173-45CC-A2C5-D5813A8E6E39Q34315588-D9F55608-8FC6-4915-A612-A411D03DA6FAQ34318028-57BCA7C6-FA5C-4C53-9EC9-4D75EA0198E5Q34449435-D573C2D6-EB2A-4BFC-B28A-2C797B97E5DCQ34466802-087F8198-6689-497D-BE5D-85A2C60E1933Q34515591-179A104B-D694-4FC4-98EA-5F2005393A2A
P2860
Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2000
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy and safety of galanta ...... e International-1 Study Group.
@en
Efficacy and safety of galanta ...... e International-1 Study Group.
@nl
type
label
Efficacy and safety of galanta ...... e International-1 Study Group.
@en
Efficacy and safety of galanta ...... e International-1 Study Group.
@nl
prefLabel
Efficacy and safety of galanta ...... e International-1 Study Group.
@en
Efficacy and safety of galanta ...... e International-1 Study Group.
@nl
P2093
P2860
P921
P1433
P1476
Efficacy and safety of galanta ...... e International-1 Study Group.
@en
P2093
G K Wilcock
S Lilienfeld
P2860
P304
P356
10.1136/BMJ.321.7274.1445
P407
P577
2000-12-01T00:00:00Z